Literature DB >> 29059447

EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough?

Michael Platten.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29059447      PMCID: PMC5737084          DOI: 10.1093/neuonc/nox167

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Authors:  John H Sampson; Amy B Heimberger; Gary E Archer; Kenneth D Aldape; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert J Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Authors:  James Schuster; Rose K Lai; Lawrence D Recht; David A Reardon; Nina A Paleologos; Morris D Groves; Maciej M Mrugala; Randy Jensen; Joachim M Baehring; Andrew Sloan; Gary E Archer; Darell D Bigner; Scott Cruickshank; Jennifer A Green; Tibor Keler; Thomas A Davis; Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2015-01-13       Impact factor: 12.300

3.  Lomustine and Bevacizumab in Progressive Glioblastoma.

Authors:  Wolfgang Wick; Thierry Gorlia; Martin Bendszus; Martin Taphoorn; Felix Sahm; Inga Harting; Alba A Brandes; Walter Taal; Julien Domont; Ahmed Idbaih; Mario Campone; Paul M Clement; Roger Stupp; Michel Fabbro; Emilie Le Rhun; Francois Dubois; Michael Weller; Andreas von Deimling; Vassilis Golfinopoulos; Jacoline C Bromberg; Michael Platten; Martin Klein; Martin J van den Bent
Journal:  N Engl J Med       Date:  2017-11-16       Impact factor: 91.245

Review 4.  Old player, new partner: EGFRvIII and cytokine receptor signaling in glioblastoma.

Authors:  Genaro R Villa; Paul S Mischel
Journal:  Nat Neurosci       Date:  2016-05-26       Impact factor: 24.884

5.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Authors:  Michael Weller; Nicholas Butowski; David D Tran; Lawrence D Recht; Michael Lim; Hal Hirte; Lynn Ashby; Laszlo Mechtler; Samuel A Goldlust; Fabio Iwamoto; Jan Drappatz; Donald M O'Rourke; Mark Wong; Mark G Hamilton; Gaetano Finocchiaro; James Perry; Wolfgang Wick; Jennifer Green; Yi He; Christopher D Turner; Michael J Yellin; Tibor Keler; Thomas A Davis; Roger Stupp; John H Sampson
Journal:  Lancet Oncol       Date:  2017-08-23       Impact factor: 41.316

Review 6.  Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Authors:  Michael Weller; Patrick Roth; Matthias Preusser; Wolfgang Wick; David A Reardon; Michael Platten; John H Sampson
Journal:  Nat Rev Neurol       Date:  2017-05-12       Impact factor: 42.937

7.  Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.

Authors:  Martin J van den Bent; Ya Gao; Melissa Kerkhof; Johan M Kros; Thierry Gorlia; Kitty van Zwieten; Jory Prince; Sjoerd van Duinen; Peter A Sillevis Smitt; Martin Taphoorn; Pim J French
Journal:  Neuro Oncol       Date:  2015-02-16       Impact factor: 12.300

8.  Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.

Authors:  Amy B Heimberger; Laura E Crotty; Gary E Archer; Kenneth R Hess; Carol J Wikstrand; Allan H Friedman; Henry S Friedman; Darell D Bigner; John H Sampson
Journal:  Clin Cancer Res       Date:  2003-09-15       Impact factor: 12.531

Review 9.  EGFRvIII-targeted vaccination therapy of malignant glioma.

Authors:  Bryan D Choi; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Roger E McLendon; Darell D Bigner; John H Sampson
Journal:  Brain Pathol       Date:  2009-10       Impact factor: 6.508

  9 in total
  7 in total

Review 1.  Vaccine Strategies in Gliomas.

Authors:  Michael Platten; Lukas Bunse; Dennis Riehl; Theresa Bunse; Katharina Ochs; Wolfgang Wick
Journal:  Curr Treat Options Neurol       Date:  2018-03-28       Impact factor: 3.598

2.  Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy.

Authors:  Ran You; Jordan Artichoker; Arja Ray; Hugo Gonzalez Velozo; Dan A Rock; Kip P Conner; Matthew F Krummel
Journal:  Cancer Immunol Res       Date:  2022-06-03       Impact factor: 12.020

3.  Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma.

Authors:  Giulia Agliardi; Anna Rita Liuzzi; Alastair Hotblack; Donatella De Feo; Nicolás Núñez; Cassandra L Stowe; Ekaterina Friebel; Francesco Nannini; Lukas Rindlisbacher; Thomas A Roberts; Rajiv Ramasawmy; Iwan P Williams; Bernard M Siow; Mark F Lythgoe; Tammy L Kalber; Sergio A Quezada; Martin A Pule; Sonia Tugues; Karin Straathof; Burkhard Becher
Journal:  Nat Commun       Date:  2021-01-19       Impact factor: 14.919

Review 4.  Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?

Authors:  Liliana Montella; Nunzio Del Gaudio; Guglielmo Bove; Mariella Cuomo; Michela Buonaiuto; Davide Costabile; Roberta Visconti; Gaetano Facchini; Lucia Altucci; Lorenzo Chiariotti; Rosa Della Monica
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

Review 5.  Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.

Authors:  Andrea Franson; Brandon L McClellan; Maria Luisa Varela; Andrea Comba; Mohammad Faisal Syed; Kaushik Banerjee; Ziwen Zhu; Nazareno Gonzalez; Marianela Candolfi; Pedro Lowenstein; Maria Graciela Castro
Journal:  Front Med (Lausanne)       Date:  2022-09-14

Review 6.  CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.

Authors:  Faroogh Marofi; Alaa S Al-Awad; Heshu Sulaiman Rahman; Alexander Markov; Walid Kamal Abdelbasset; Yulianna Ivanovna Enina; Mahnaz Mahmoodi; Ali Hassanzadeh; Mahboubeh Yazdanifar; Max Stanley Chartrand; Mostafa Jarahian
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 7.  Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).

Authors:  Alice Giotta Lucifero; Sabino Luzzi
Journal:  Brain Sci       Date:  2021-03-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.